Na Xie1, Zheng Tan1,2, Sami Banerjee1, Huachun Cui1, Jing Ge1, Rui-Ming Liu1, Karen Bernard1, Victor J Thannickal1, Gang Liu1. 1. 1 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; and. 2. 2 Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract
RATIONALE: Dysregulation of cellular metabolism has been shown to participate in several pathologic processes. However, the role of metabolic reprogramming is not well appreciated in the pathogenesis of organ fibrosis. OBJECTIVES: To determine if glycolytic reprogramming participates in the pathogenesis of lung fibrosis and assess the therapeutic potential of glycolytic inhibition in treating lung fibrosis. METHODS: A cell metabolism assay was performed to determine glycolytic flux and mitochondrial respiration. Lactate levels were measured to assess glycolysis in fibroblasts and lungs. Glycolytic inhibition by genetic and pharmacologic approaches was used to demonstrate the critical role of glycolysis in lung fibrosis. MEASUREMENTS AND MAIN RESULTS: Augmentation of glycolysis is an early and sustained event during myofibroblast differentiation, which is dependent on the increased expression of critical glycolytic enzymes, in particular, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3). Augmented glycolysis contributes to the stabilization of hypoxia-inducible factor 1-α, a master regulator of glycolytic enzymes implicated in organ fibrosis, by increasing cellular levels of tricarboxylic acid cycle intermediate succinate in lung myofibroblasts. Inhibition of glycolysis by the PFKFB3 inhibitor 3PO or genomic disruption of the PFKFB3 gene blunted the differentiation of lung fibroblasts into myofibroblasts, and attenuated profibrotic phenotypes in myofibroblasts isolated from the lungs of patients with idiopathic pulmonary fibrosis. Inhibition of glycolysis by 3PO demonstrates therapeutic benefit in bleomycin-induced and transforming growth factor-β1-induced lung fibrosis in mice. CONCLUSIONS: Our data support the novel concept of glycolytic reprogramming in the pathogenesis of lung fibrosis and provide proof-of-concept that targeting this pathway may be efficacious in treating fibrotic disorders, such as idiopathic pulmonary fibrosis.
RATIONALE: Dysregulation of cellular metabolism has been shown to participate in several pathologic processes. However, the role of metabolic reprogramming is not well appreciated in the pathogenesis of organ fibrosis. OBJECTIVES: To determine if glycolytic reprogramming participates in the pathogenesis of lung fibrosis and assess the therapeutic potential of glycolytic inhibition in treating lung fibrosis. METHODS: A cell metabolism assay was performed to determine glycolytic flux and mitochondrial respiration. Lactate levels were measured to assess glycolysis in fibroblasts and lungs. Glycolytic inhibition by genetic and pharmacologic approaches was used to demonstrate the critical role of glycolysis in lung fibrosis. MEASUREMENTS AND MAIN RESULTS: Augmentation of glycolysis is an early and sustained event during myofibroblast differentiation, which is dependent on the increased expression of critical glycolytic enzymes, in particular, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3). Augmented glycolysis contributes to the stabilization of hypoxia-inducible factor 1-α, a master regulator of glycolytic enzymes implicated in organ fibrosis, by increasing cellular levels of tricarboxylic acid cycle intermediate succinate in lung myofibroblasts. Inhibition of glycolysis by the PFKFB3 inhibitor 3PO or genomic disruption of the PFKFB3 gene blunted the differentiation of lung fibroblasts into myofibroblasts, and attenuated profibrotic phenotypes in myofibroblasts isolated from the lungs of patients with idiopathic pulmonary fibrosis. Inhibition of glycolysis by 3PO demonstrates therapeutic benefit in bleomycin-induced and transforming growth factor-β1-induced lung fibrosis in mice. CONCLUSIONS: Our data support the novel concept of glycolytic reprogramming in the pathogenesis of lung fibrosis and provide proof-of-concept that targeting this pathway may be efficacious in treating fibrotic disorders, such as idiopathic pulmonary fibrosis.
Authors: James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown Journal: Nat Rev Mol Cell Biol Date: 2002-05 Impact factor: 94.444
Authors: Zheng Tan; Na Xie; Sami Banerjee; Huachun Cui; Mingui Fu; Victor J Thannickal; Gang Liu Journal: J Biol Chem Date: 2014-11-18 Impact factor: 5.157
Authors: Robert Matthew Kottmann; Ajit A Kulkarni; Katie A Smolnycki; Elizabeth Lyda; Thinesh Dahanayake; Rami Salibi; Sylvie Honnons; Carolyn Jones; Nancy G Isern; Jian Z Hu; Steven D Nathan; Geraldine Grant; Richard P Phipps; Patricia J Sime Journal: Am J Respir Crit Care Med Date: 2012-08-23 Impact factor: 21.405
Authors: David Dolivo; Adrian Rodrigues; Lauren Sun; Yingxing Li; Chun Hou; Robert Galiano; Seok Jong Hong; Thomas Mustoe Journal: Cell Mol Life Sci Date: 2021-06-08 Impact factor: 9.261
Authors: Mehrdad Pourfathi; Yi Xin; Stephen J Kadlecek; Maurizio F Cereda; Harrilla Profka; Hooman Hamedani; Sarmad M Siddiqui; Kai Ruppert; Nicholas A Drachman; Jennia N Rajaei; Rahim R Rizi Journal: Magn Reson Med Date: 2017-01-11 Impact factor: 4.668
Authors: Huachun Cui; Na Xie; Dingyuan Jiang; Sami Banerjee; Jing Ge; Yan Y Sanders; Gang Liu Journal: Am J Respir Cell Mol Biol Date: 2019-10 Impact factor: 6.914
Authors: Erin M O'Leary; Yufeng Tian; Recep Nigdelioglu; Leah J Witt; Rengul Cetin-Atalay; Angelo Y Meliton; Parker S Woods; Lucas M Kimmig; Kaitlyn A Sun; Gizem A Gökalp; Gökhan M Mutlu; Robert B Hamanaka Journal: Am J Respir Cell Mol Biol Date: 2020-11 Impact factor: 6.914